zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Michael Kreuter, M.D.

Center for Interstitial and Rare Lung Diseases &

Department of Pulmonology and Critical Care Medicine

Thoraxklinik, Heidelberg University Hospital

Röntgenstraße 1

69120 Heidelberg

Phone:+49 6221 396-1201

Opens window for sending emailE-Mail

Opens external link in new windowHomepage

 

 

Research Interests:

  • Interstitial lung disease
  • COPD
  • Epidemiology of pulmonary diseases
  • Smoking prevention and cessation

 

 

Short CV

1992-1999Medical School Marburg, Germany
1999-2001Residency, Internal Medicine, University of Münster, Germany
2001-2002Research Associate, Children´s Hospital, Harvard University, Boston, USA
2002-2005Residency, Internal Medicine, University of Münster, Germany
2005-2010Residency, Department of Pneumology & Respiratory Critical Care Medicine and Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Germany
since 2010Consultant, Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik at Heidelberg University Hospital
since 2010Head of the Center for Interstitial and Rare Lung Diseases, Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik at Heidelberg University Hospital
since 2015Professor, Heidelberg University

 

 

Honours & Awards

2001German Cancer Association – Dr. Mildred Scheel Stipendium – Research Fellowship
2015Science Award of the Patient Support Group Lungenfibrose e.V.

 

 

Memberships/Committee Assignments

2008-Board member of the German Society of Pulmonology
2011-Board member of the South German Society of Pulmonology
2012-Fellow of the College of Chest Physicans (FCCP) of the American College of Chest Physicans (ACCP)
2012-Member of the long range planning committee of the European Respiratory Society (ERS)
2013-Board Member of the Scientific Association for the therapy of pulmonary diseases (WATL)
2013-Principle Investigator of the Translational Lung Research Center Heidelberg (TLRC) and the German Center for Lung Research (DZL)
2014-Secretary for research and teaching, South German Society of Pulmonology
2016-Chief Medical Advisor of the Patient Support Group Lungenfibrose e.V.

Projects

  1. Interstitial lung disease: The group of Michael Kreuter focusses on all aspects of interstitial lung diseases : He leads a registry for interstitial lung diseases of the DZL and is steering committee member of a huge IPF registry in close collaboration with other DZL partners. Further investigations deal with the role of comorbidities and its implications on treatment and prognosis, the identification of risk factors and the establishment of clinical, radiological and serum biomarkers. Another aspect of the groups research covers diagnosis and therapy as well as its improvement in different ILDs. All projects are implemented into the DZL with various other partners within the DZL community.

  2. Smoking prevention and cessation: As smokingcontinues to be the leading preventable cause of mortality and morbidity in the world the group´s focus is on prevention of the onset of smoking and on smoking cessation. One of the largest smoking cessation trials in Germany implementing short term counseling is lead by the Thoraxklinik Heidelberg.

Team

Head of Department Internal Medicine, Pulmonology and Critical Care Medicine

Prof. Dr. Felix Herth

 

Senior Scientists

Dr. Eva Brunnemer

Dr. Nicolas Kahn

Dr. Ute Oltmanns

Dr. Karin Palmowski

Dr. Claudia Bauer (Scientific project management)

Dr. Simone Hummler (Clinical study investigator)

Dr. Julia Benstz (Clinical study investigator)

 

Medical Scientists

Mrs. Svenja Ehlers-Tenenbaum

Dr. Stella Piel

Dr. Julia Wälscher

Dr. Lars Kehler

 

Medical student

Mrs. Miriam Schaaf

 

Study nurse

Mrs. Beate Schaufler
Mrs. Dagmar Altner

Selected Publications

  1. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM (2016). Unfavourable effects of medically indicated oral anticoagulants on survival in IPF. Eur Resp J, in press

  2. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJF (2016). Impact of comorbidities on mortality in patients with Idiopathic Pulmonary Fibrosis. PlosOne, in press.

  3. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJF, Costabel U (2016). Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med, in press.

  4. Colombi D, Ehlers-Tenenbaum S, Palmowski K, Heussel C, Sverzellati N, Silva M, Eichinger M, Kreuter M (2016). Spontaneous Pneumomediastinum as a Potential Predictor of Mortality in Patients with Idiopathic Pulmonary Fibrosis. Respiration, in press

  5. Bahmer T., Kirsten A., Waschki B., Rabe K., Magnussen H., Kirsten D., Gramm M., Hummler S., Brunnemer E., Kreuter M*., Watz H* *equal contribution (2016). Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis, Respiration, in press

  6. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M (2016). Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, in press

  7. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M (2016). 3-years follow up of a randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb) – TREAT. J Thorac Oncol, 11: 85-93

  8. Baroke E, Heussel CP, Warth A, Eichinger M, Oltmanns U, Palmowski K, Herth F, Kreuter M (2016). Pleuroparenchymal fibroelastosis in association with carcinomas. Respirology, 21: 191-194

  9. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H, Schnabel PA, Heußel CP, Puderbach M, Herth FJF, Warth A (2015). Treatment and Outcome of Lung Cancer in Idiopathic Interstitial Pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 31: 266-274

  10. Colombi D, Dinkel J, Weinheimer O, Obermayer B, Nabers D, Bauer C, Oltmanns U, Palmowski K, Herth FJ, Kauczor H-U, Sverzellati N, Kreuter M*, Heussel CP* (*equal contribution) (2015). Visual vs Fully Automatic Histogram-based Quantitative Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression using Sequential Multidetector Computed Tomography (MDCT). PLoS One; 10(6):e0130653
Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen